Synthesis, Crystal Structure, Antitumor Activities and Docking Study of 1-(2-(1H-Indol-3-yl)ethyl)-3-(2-methoxyphenyl)urea

Abstract

The title compound, 1-(2-(1H-indo1-3-yl)ethyl)-3-(2-methoxyphenyl)urea (C18H19N3O2, M-r = 309.36) has been synthesized, and its structure was characterized by H-1-NMR, C-13-NMR, ESI-MS and single-crystal X-ray diffraction. It crystallizes in the monoclinic space group P2(1)/c with a = 16.2774(15), b = 11.1082(10), c = 9.0819(3) angstrom, beta = 103.09(9)degrees, V = 1599.5(3) angstrom(3), Z = 4, T = 293(2) K, mu(MoK alpha) = 0.086 mm(-1), D-c = 1.285 g/cm(3), F(000) = 656 and GOOF = 0.981. 5973 reflections were measured (7.04 2 sigma(I)) and wR = 0.1976 (all data). The antitumor activity of the title compound was analyzed by MTT assay. Meanwhile, to rationalize its potencies in the CDK4 target, the title compound was docked into CDK4 protein and the interactions with the active site residues were analyzed.